Published in Vaccine Weekly, July 26th, 2006
According to the review, "Drugs that target extracellular molecules and intracellular pathways remain an area of active research in prostate cancer. Although preclinical data suggest that new drugs can modulate or slow prostate tumor proliferation, responses in man such as disease stabilization or regression are not as dramatic as those seen in preclinical models. Other approaches including carbohydrate and cellular product vaccines, cytokines, and monoclonal antibodies either alone or with radio-pharmaceuticals, are being used to seek...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.